調査レポート | • レポートコード：GIR-2104Z00334 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、急性骨髄性白血病治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。急性骨髄性白血病治療の種類別市場規模（DC摂生、AVD摂生、VCD摂生）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・急性骨髄性白血病治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Valeo、Continental、Magna International、Hitachi Automotive、Fujitsu、Ficosa ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：DC摂生、AVD摂生、VCD摂生 ・用途別分析2016年-2026年：病院、診療所、その他 ・急性骨髄性白血病治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・急性骨髄性白血病治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・急性骨髄性白血病治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・急性骨髄性白血病治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・急性骨髄性白血病治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Acute Myeloid Leukemia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Acute Myeloid Leukemia Treatment size is estimated to be USD 774.8 million in 2025 from USD 578.1 million in 2019, with a change XX% between 2019 and 2020. The global Acute Myeloid Leukemia Treatment market size is expected to grow at a CAGR of 7.6% for the next five years.
Market segmentation
Acute Myeloid Leukemia Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
DC regimen
AVD Regimen
VCD regimen
Market segment by Application, can be divided into
Hospital
Clinic
Others
Market segment by players, this report covers
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Acute Myeloid Leukemia Treatment
1.2 Classification of Acute Myeloid Leukemia Treatment by Type
1.2.1 Overview: Global Acute Myeloid Leukemia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Acute Myeloid Leukemia Treatment Revenue Market Share by Type in 2020
1.2.3 DC regimen
1.2.4 AVD Regimen
1.2.5 VCD regimen
1.3 Global Acute Myeloid Leukemia Treatment Market by Application
1.3.1 Overview: Global Acute Myeloid Leukemia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Acute Myeloid Leukemia Treatment Market Size & Forecast
1.5 Global Acute Myeloid Leukemia Treatment Market Size and Forecast by Region
1.5.1 Global Acute Myeloid Leukemia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Acute Myeloid Leukemia Treatment Market Size by Region, (2016-2021)
1.5.3 North America Acute Myeloid Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Acute Myeloid Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Acute Myeloid Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Acute Myeloid Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Acute Myeloid Leukemia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Acute Myeloid Leukemia Treatment Market Drivers
1.6.2 Acute Myeloid Leukemia Treatment Market Restraints
1.6.3 Acute Myeloid Leukemia Treatment Trends Analysis
2 Company Profiles
2.1 Ambit Biosciences Corporation
2.1.1 Ambit Biosciences Corporation Details
2.1.2 Ambit Biosciences Corporation Major Business
2.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Product and Solutions
2.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Ambit Biosciences Corporation Recent Developments and Future Plans
2.2 Celgene Corporation
2.2.1 Celgene Corporation Details
2.2.2 Celgene Corporation Major Business
2.2.3 Celgene Corporation Acute Myeloid Leukemia Treatment Product and Solutions
2.2.4 Celgene Corporation Acute Myeloid Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Celgene Corporation Recent Developments and Future Plans
2.3 Cephalon
2.3.1 Cephalon Details
2.3.2 Cephalon Major Business
2.3.3 Cephalon Acute Myeloid Leukemia Treatment Product and Solutions
2.3.4 Cephalon Acute Myeloid Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Cephalon Recent Developments and Future Plans
2.4 Clavis Pharma
2.4.1 Clavis Pharma Details
2.4.2 Clavis Pharma Major Business
2.4.3 Clavis Pharma Acute Myeloid Leukemia Treatment Product and Solutions
2.4.4 Clavis Pharma Acute Myeloid Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Clavis Pharma Recent Developments and Future Plans
2.5 Eisai
2.5.1 Eisai Details
2.5.2 Eisai Major Business
2.5.3 Eisai Acute Myeloid Leukemia Treatment Product and Solutions
2.5.4 Eisai Acute Myeloid Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Eisai Recent Developments and Future Plans
2.6 Genzyme Corporation
2.6.1 Genzyme Corporation Details
2.6.2 Genzyme Corporation Major Business
2.6.3 Genzyme Corporation Acute Myeloid Leukemia Treatment Product and Solutions
2.6.4 Genzyme Corporation Acute Myeloid Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Genzyme Corporation Recent Developments and Future Plans
2.7 Sunesis Pharmaceuticals
2.7.1 Sunesis Pharmaceuticals Details
2.7.2 Sunesis Pharmaceuticals Major Business
2.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Product and Solutions
2.7.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Sunesis Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Acute Myeloid Leukemia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Myeloid Leukemia Treatment Players Market Share
3.2.2 Top 10 Acute Myeloid Leukemia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Acute Myeloid Leukemia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Acute Myeloid Leukemia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Acute Myeloid Leukemia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Acute Myeloid Leukemia Treatment Revenue Market Share by Application (2016-2021)
5.2 Acute Myeloid Leukemia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Acute Myeloid Leukemia Treatment Revenue by Type (2016-2026)
6.2 North America Acute Myeloid Leukemia Treatment Revenue by Application (2016-2026)
6.3 North America Acute Myeloid Leukemia Treatment Market Size by Country
6.3.1 North America Acute Myeloid Leukemia Treatment Revenue by Country (2016-2026)
6.3.2 United States Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Acute Myeloid Leukemia Treatment Revenue by Type (2016-2026)
7.2 Europe Acute Myeloid Leukemia Treatment Revenue by Application (2016-2026)
7.3 Europe Acute Myeloid Leukemia Treatment Market Size by Country
7.3.1 Europe Acute Myeloid Leukemia Treatment Revenue by Country (2016-2026)
7.3.2 Germany Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.3 France Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Acute Myeloid Leukemia Treatment Market Size by Region
8.3.1 Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Region (2016-2026)
8.3.2 China Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.5 India Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Acute Myeloid Leukemia Treatment Revenue by Type (2016-2026)
9.2 South America Acute Myeloid Leukemia Treatment Revenue by Application (2016-2026)
9.3 South America Acute Myeloid Leukemia Treatment Market Size by Country
9.3.1 South America Acute Myeloid Leukemia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Acute Myeloid Leukemia Treatment Market Size by Country
10.3.1 Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Acute Myeloid Leukemia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Acute Myeloid Leukemia Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Acute Myeloid Leukemia Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Acute Myeloid Leukemia Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Acute Myeloid Leukemia Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Acute Myeloid Leukemia Treatment Revenue Market Share by Region (2021-2026)
Table 6. Ambit Biosciences Corporation Corporate Information, Head Office, and Major Competitors
Table 7. Ambit Biosciences Corporation Major Business
Table 8. Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Product and Solutions
Table 9. Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Celgene Corporation Corporate Information, Head Office, and Major Competitors
Table 11. Celgene Corporation Major Business
Table 12. Celgene Corporation Acute Myeloid Leukemia Treatment Product and Solutions
Table 13. Celgene Corporation Acute Myeloid Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Cephalon Corporate Information, Head Office, and Major Competitors
Table 15. Cephalon Major Business
Table 16. Cephalon Acute Myeloid Leukemia Treatment Product and Solutions
Table 17. Cephalon Acute Myeloid Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Clavis Pharma Corporate Information, Head Office, and Major Competitors
Table 19. Clavis Pharma Major Business
Table 20. Clavis Pharma Acute Myeloid Leukemia Treatment Product and Solutions
Table 21. Clavis Pharma Acute Myeloid Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Eisai Corporate Information, Head Office, and Major Competitors
Table 23. Eisai Major Business
Table 24. Eisai Acute Myeloid Leukemia Treatment Product and Solutions
Table 25. Eisai Acute Myeloid Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Genzyme Corporation Corporate Information, Head Office, and Major Competitors
Table 27. Genzyme Corporation Major Business
Table 28. Genzyme Corporation Acute Myeloid Leukemia Treatment Product and Solutions
Table 29. Genzyme Corporation Acute Myeloid Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Sunesis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Sunesis Pharmaceuticals Major Business
Table 32. Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Product and Solutions
Table 33. Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Global Acute Myeloid Leukemia Treatment Revenue (USD Million) by Players (2019-2021)
Table 35. Global Acute Myeloid Leukemia Treatment Revenue Share by Players (2019-2021)
Table 36. Breakdown of Acute Myeloid Leukemia Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Acute Myeloid Leukemia Treatment Players Head Office, Products and Services Provided
Table 38. Acute Myeloid Leukemia Treatment Mergers & Acquisitions in the Past Five Years
Table 39. Acute Myeloid Leukemia Treatment New Entrants and Expansion Plans
Table 40. Global Acute Myeloid Leukemia Treatment Revenue (USD Million) by Type (2016-2021)
Table 41. Global Acute Myeloid Leukemia Treatment Revenue Share by Type (2016-2021)
Table 42. Global Acute Myeloid Leukemia Treatment Revenue Forecast by Type (2021-2026)
Table 43. Global Acute Myeloid Leukemia Treatment Revenue by Application (2016-2021)
Table 44. Global Acute Myeloid Leukemia Treatment Revenue Forecast by Application (2021-2026)
Table 45. North America Acute Myeloid Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 46. North America Acute Myeloid Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 47. North America Acute Myeloid Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 48. North America Acute Myeloid Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 49. North America Acute Myeloid Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 50. North America Acute Myeloid Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 51. Europe Acute Myeloid Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 52. Europe Acute Myeloid Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 53. Europe Acute Myeloid Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 54. Europe Acute Myeloid Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 55. Europe Acute Myeloid Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 56. Europe Acute Myeloid Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 57. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 58. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 59. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 60. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 61. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Region (2016-2021) & (USD Million)
Table 62. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue by Region (2021-2026) & (USD Million)
Table 63. South America Acute Myeloid Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 64. South America Acute Myeloid Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 65. South America Acute Myeloid Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 66. South America Acute Myeloid Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 67. South America Acute Myeloid Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 68. South America Acute Myeloid Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 70. Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 71. Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 72. Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 73. Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 74. Middle East & Africa Acute Myeloid Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Acute Myeloid Leukemia Treatment Picture
Figure 2. Global Acute Myeloid Leukemia Treatment Revenue Market Share by Type in 2020
Figure 3. DC regimen
Figure 4. AVD Regimen
Figure 5. VCD regimen
Figure 6. Acute Myeloid Leukemia Treatment Revenue Market Share by Application in 2020
Figure 7. Hospital Picture
Figure 8. Clinic Picture
Figure 9. Others Picture
Figure 10. Global Acute Myeloid Leukemia Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Acute Myeloid Leukemia Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Acute Myeloid Leukemia Treatment Revenue Market Share by Region (2016-2026)
Figure 13. Global Acute Myeloid Leukemia Treatment Revenue Market Share by Region in 2020
Figure 14. North America Acute Myeloid Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Acute Myeloid Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Acute Myeloid Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Acute Myeloid Leukemia Treatment Market Drivers
Figure 19. Acute Myeloid Leukemia Treatment Market Restraints
Figure 20. Acute Myeloid Leukemia Treatment Market Trends
Figure 21. Ambit Biosciences Corporation Recent Developments and Future Plans
Figure 22. Celgene Corporation Recent Developments and Future Plans
Figure 23. Cephalon Recent Developments and Future Plans
Figure 24. Clavis Pharma Recent Developments and Future Plans
Figure 25. Eisai Recent Developments and Future Plans
Figure 26. Genzyme Corporation Recent Developments and Future Plans
Figure 27. Sunesis Pharmaceuticals Recent Developments and Future Plans
Figure 29. Global Acute Myeloid Leukemia Treatment Revenue Share by Players in 2020
Figure 30. Acute Myeloid Leukemia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 31. Global Top 3 Players Acute Myeloid Leukemia Treatment Revenue Market Share in 2020
Figure 32. Global Top 10 Players Acute Myeloid Leukemia Treatment Revenue Market Share in 2020
Figure 33. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 34. Global Acute Myeloid Leukemia Treatment Revenue Share by Type in 2020
Figure 35. Global Acute Myeloid Leukemia Treatment Market Share Forecast by Type (2021-2026)
Figure 36. Global Acute Myeloid Leukemia Treatment Revenue Share by Application in 2020
Figure 37. Global Acute Myeloid Leukemia Treatment Market Share Forecast by Application (2021-2026)
Figure 38. North America Acute Myeloid Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 39. North America Acute Myeloid Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 40. North America Acute Myeloid Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 41. United States Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Acute Myeloid Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 45. Europe Acute Myeloid Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 46. Europe Acute Myeloid Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 47. Germany Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Acute Myeloid Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 53. Asia-Pacific Acute Myeloid Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Acute Myeloid Leukemia Treatment Revenue Market Share by Region (2016-2026)
Figure 55. China Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Japan Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. South Korea Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. India Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Southeast Asia Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Australia Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South America Acute Myeloid Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 62. South America Acute Myeloid Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 63. South America Acute Myeloid Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 64. Brazil Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Argentina Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Middle East and Africa Acute Myeloid Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 67. Middle East and Africa Acute Myeloid Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 68. Middle East and Africa Acute Myeloid Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 69. Turkey Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Saudi Arabia Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. UAE Acute Myeloid Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Methodology
Figure 73. Research Process and Data Source
世界の急性骨髄性白血病（AML）治療市場規模・現状・予測（2021年-2027年） Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90…- 世界の急性骨髄性白血病（AML）市場規模・現状・予測（2021年-2027年） Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical …
- 世界の急性骨髄性白血病（AML）治療市場規模・現状・予測（2021年-2027年） Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90…
- 世界のT細胞急性リンパ芽球性白血病治療市場 2021：企業別、地域別、種類・用途別 The T-cell Acute Lymphoblastic Leukemia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optim…
- 世界の急性リンパ芽球性白血病（ALL）治療市場規模・現状・予測（2021年-2027年） Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. Market Analysis and Insights: Global Acute Lymphoblastic Leukemia Treatment Market The global Acute Lymphoblastic Leukemia Treatment market si…